Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Expands By 859.7%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 1,430,000 shares, an increase of 859.7% from the March 31st total of 149,000 shares. Based on an average daily volume of 632,000 shares, the short-interest ratio is presently 2.3 days.

Analysts Set New Price Targets

CLDI has been the subject of several research analyst reports. HC Wainwright decreased their price objective on shares of Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. Robert W. Baird decreased their price objective on shares of Calidi Biotherapeutics from $9.00 to $4.50 and set an “outperform” rating for the company in a research note on Thursday, March 21st.

Calidi Biotherapeutics Stock Performance

NYSEAMERICAN CLDI opened at $0.16 on Friday. Calidi Biotherapeutics has a 1 year low of $0.14 and a 1 year high of $13.79.

Institutional Investors Weigh In On Calidi Biotherapeutics

An institutional investor recently bought a new position in Calidi Biotherapeutics stock. Spectrum Asset Management Inc. NB CA purchased a new position in shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 166,494 shares of the company’s stock, valued at approximately $94,000. Spectrum Asset Management Inc. NB CA owned 0.47% of Calidi Biotherapeutics at the end of the most recent reporting period. 12.53% of the stock is currently owned by institutional investors and hedge funds.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.